Literature DB >> 9561487

Physiologically based pharmacokinetic modeling of a homologous series of barbiturates in the rat: a sensitivity analysis.

I A Nestorov1, L J Aarons, M Rowland.   

Abstract

Sensitivity analysis studies the effects of the inherent variability and uncertainty in model parameters on the model outputs and may be a useful tool at all stages of the pharmacokinetic modeling process. The present study examined the sensitivity of a whole-body physiologically based pharmacokinetic (PBPK) model for the distribution kinetics of nine 5-n-alkyl-5-ethyl barbituric acids in arterial blood and 14 tissues (lung, liver, kidney, stomach, pancreas, spleen, gut, muscle, adipose, skin, bone, heart, brain, testes) after i.v. bolus administration to rats. The aims were to obtain new insights into the model used, to rank the model parameters involved according to their impact on the model outputs and to study the changes in the sensitivity induced by the increase in the lipophilicity of the homologues on ascending the series. Two approaches for sensitivity analysis have been implemented. The first, based on the Matrix Perturbation Theory, uses a sensitivity index defined as the normalized sensitivity of the 2-norm of the model compartmental matrix to perturbations in its entries. The second approach uses the traditional definition of the normalized sensitivity function as the relative change in a model state (a tissue concentration) corresponding to a relative change in a model parameter. Autosensitivity has been defined as sensitivity of a state to any of its parameters; cross-sensitivity as the sensitivity of a state to any other states' parameters. Using the two approaches, the sensitivity of representative tissue concentrations (lung, liver, kidney, stomach, gut, adipose, heart, and brain) to the following model parameters: tissue-to-unbound plasma partition coefficients, tissue blood flows, unbound renal and intrinsic hepatic clearance, permeability surface area product of the brain, have been analyzed. Both the tissues and the parameters were ranked according to their sensitivity and impact. The following general conclusions were drawn: (i) the overall sensitivity of the system to all parameters involved is small due to the weak connectivity of the system structure; (ii) the time course of both the auto- and cross-sensitivity functions for all tissues depends on the dynamics of the tissues themselves, e.g., the higher the perfusion of a tissue, the higher are both its cross-sensitivity to other tissues' parameters and the cross-sensitivities of other tissues to its parameters; and (iii) with a few exceptions, there is not a marked influence of the lipophilicity of the homologues on either the pattern or the values of the sensitivity functions. The estimates of the sensitivity and the subsequent tissue and parameter rankings may be extended to other drugs, sharing the same common structure of the whole body PBPK model, and having similar model parameters. Results show also that the computationally simple Matrix Perturbation Analysis should be used only when an initial idea about the sensitivity of a system is required. If comprehensive information regarding the sensitivity is needed, the numerically expensive Direct Sensitivity Analysis should be used.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9561487     DOI: 10.1023/a:1025740909016

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  18 in total

1.  An extended physiological pharmacokinetic model of methadone disposition in the rat: validation and sensitivity analysis.

Authors:  J L Gabrielsson; T Groth
Journal:  J Pharmacokinet Biopharm       Date:  1988-04

2.  Absorption and excretion of drugs. XXXII. Absorption of barbituric acid derivatives from rat small intestine.

Authors:  K Kakemi; T Arita; R Hori; R Konishi
Journal:  Chem Pharm Bull (Tokyo)       Date:  1967-12       Impact factor: 1.645

3.  Effect of parameter variability on physiologically-based pharmacokinetic model predicted drug concentrations.

Authors:  P Varkonyi; J V Bruckner; J M Gallo
Journal:  J Pharm Sci       Date:  1995-03       Impact factor: 3.534

4.  Tissue distribution of fentanyl and alfentanil in the rat cannot be described by a blood flow limited model.

Authors:  S Björkman; D R Stanski; H Harashima; R Dowrie; S R Harapat; D R Wada; W F Ebling
Journal:  J Pharmacokinet Biopharm       Date:  1993-06

Review 5.  Physiological parameters in laboratory animals and humans.

Authors:  B Davies; T Morris
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

6.  Physiologic modeling of cyclosporin kinetics in rat and man.

Authors:  A Bernareggi; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

Review 7.  Incorporation of pharmacokinetics in noncancer risk assessment: example with chloropentafluorobenzene.

Authors:  H J Clewell; B M Jarnot
Journal:  Risk Anal       Date:  1994-06       Impact factor: 4.000

8.  Structure-pharmacokinetic relationships among the barbiturates in the rat.

Authors:  S Toon; M Rowland
Journal:  J Pharmacol Exp Ther       Date:  1983-06       Impact factor: 4.030

9.  Comparative physiological pharmacokinetics of fentanyl and alfentanil in rats and humans based on parametric single-tissue models.

Authors:  S Björkman; D R Wada; D R Stanski; W F Ebling
Journal:  J Pharmacokinet Biopharm       Date:  1994-10

10.  Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125.

Authors:  R Kawai; M Lemaire; J L Steimer; A Bruelisauer; W Niederberger; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1994-10
View more
  16 in total

1.  Sensitivity analysis of pharmacokinetic and pharmacodynamic systems: I. A structural approach to sensitivity analysis of physiologically based pharmacokinetic models.

Authors:  I A Nestorov
Journal:  J Pharmacokinet Biopharm       Date:  1999-12

Review 2.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Physiologically based pharmacokinetic model for composite nanodevices: effect of charge and size on in vivo disposition.

Authors:  Donald E Mager; Vidhi Mody; Chao Xu; Alan Forrest; Wojciech G Lesniak; Shraddha S Nigavekar; Muhammed T Kariapper; Leah Minc; Mohamed K Khan; Lajos P Balogh
Journal:  Pharm Res       Date:  2012-06-12       Impact factor: 4.200

4.  Fuzzy simulation of pharmacokinetic models: case study of whole body physiologically based model of diazepam.

Authors:  Ivelina I Gueorguieva; Ivan A Nestorov; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-06       Impact factor: 2.745

5.  Uncertainty analysis in pharmacokinetics and pharmacodynamics: application to naratriptan.

Authors:  Ivelina Gueorguieva; Ivan A Nestorov; Leon Aarons; Malcolm Rowland
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

6.  Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: diazepam case study.

Authors:  Ivelina Gueorguieva; Ivan A Nestorov; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12-20       Impact factor: 2.745

7.  Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition.

Authors:  Anson K Abraham; Wojciech Krzyzanski; Donald E Mager
Journal:  AAPS J       Date:  2007-06-08       Impact factor: 4.009

Review 8.  Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Authors:  Kathryn Ball; François Bouzom; Jean-Michel Scherrmann; Bernard Walther; Xavier Declèves
Journal:  AAPS J       Date:  2013-06-20       Impact factor: 4.009

Review 9.  Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data.

Authors:  Nikolaos Tsamandouras; Amin Rostami-Hodjegan; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

10.  Lumping of whole-body physiologically based pharmacokinetic models.

Authors:  I A Nestorov; L J Aarons; P A Arundel; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1998-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.